Sheet 1 of 2 Attorney Docket No. U.S. DEPARTMENT OF COMMERCE 50026/012004 SUBSTITUTE FORM PTO-1449 (MODIFIED) PATENT AND TRADEMARK OFFICE Serial No. 09/905,591 Applicant Keiya Ozawa et al. INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date July 13, 2001 (Use several sheets if necessary) Group 1634 February 19, 2004 (37 C.F.R. § 1.98(b)) **IDS Filed** U.S. PATENTS Patentee Class Subclass Filing Date Examiner's Patent Number Issue Date Initials (If Appropriate) 5,686,281 Nov. 11, 1997 Roberts 5,747,292 May 5, 1998 Greenberg et al. O'Malley et al. 6,416,998 Jul. 9, 2002 FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION Subclass Translation Examiner's Document Publication Country or Patent Office (Yes/No) Initials Number Date OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Anderson, "Human Gene Therapy" Nature 392(Supp.):25-30 (1998). Cheok, "Cancer Fears Cast Doubts on Future of Gene Therapy" Nature 421:678 (2003). Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" Journal of Hepatology 39:731-737 (2003). Finer et al., "kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes" Blood 83:43-50 (1994). Juengst, "What Next for Human Gene Therapy" BMJ 326:1410-1411 (2003). Kakuta et al., "Inhibition of B16 Melanoma Experimental Metastasis by Interferon-γ through Direct Inhibition of Cell Proliferation and Activation of Antitumour Host Mechanisms," Immunology 105:92-100 (2002). Kmiec "Gene Therapy" American Scientist 87:240-247 (1999). Marcinkowska and Więdłocha "Steroid Signal Transduction Activated at the Cell Membrane: from Plants to Animals," Acta Biochimica Polonica 49(3):735-745 (2002). Maruyama et al., "Proliferation and Erythroid Differentiation through the Cytoplasmic Domain of the Erythropoletin Receptor," The Journal of Biological Chemistry, 269(8):5976-5980 (1994). Morgenstern and Land "Advanced Mammalian Gene Transfer: High Titre Retroviral Vectors with Multiple Drug Selection Markers and a Complementary Helper-Free Packaging Cell Line" Nucleic Acids Research 18:3587-3596 (1990). **EXAMINER** DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

DEMARK							5551.4.4.		
SUBSTITUTE (MODIFIED)  (37 C.F.R. § 1  Examiner's Initials	ENT OF COMMERCE TRADEMARK OFFICE  (1)  U.S. PATENTS  Patent	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed		50026/012004 09/905,591 Keiya Ozawa et al. July 13, 2001 1634 February 19, 2004 Subclass Filing Date					
imuais	.e						(If Appropriate)		
			<u> </u>			<u></u>			
	FORE	IGN PATENT OR	PUBLISHED FOREIGN	PATENT AF	PLICATIO	N	<u></u>		
Examiner's Initials	Document Number	Publication Date	Country o Patent Office		Class	Subclass	Translation (Yes/No)		
		<u> </u>							
	OTHER DOCL	IMENTS (INCLUDI	ING AUTHOR, TITLE, D	ATE, PLACE	OF PUBI	LICATION)			
BIL	O'Farrell et al., "IL Evidence for Stat	10 Inhibits Macrop 3-Dependent and -	phage Activation and Pr Independent Pathways,	oliferation by The EMBO	Distinct S	ignaling Med 7(4):1006-10	hanisms: 18 (1998).		
	Roussel et al., "Colony-Stimulating Factor 1-Mediated Regulation of a Chimeric c-fms/v-fms Receptor Containing the v-fms-Encoded Tyrosine Kinase Domain" Proc. Natl. Acad. Sci. USA 85:5903-5907 (1988).								
	Verma and Somia, "Gene Therapy-Promises, Problems and Prospects," Nature 389:239-242 (1997).  Wang et al., "Yeast Two-Hybrid System Demonstrates that Estrogen Receptor Dirnerization is Ligand-Dependent in Vivo," The Journal of Biological Chemistry, 270(40):23322-23329 (1995).								
BXK	Wimmel et al., "Autocrine Growth Inhibition by Transforming Growth Factor β-1 (TGFβ-1) in Human Neuroendocrine Tumour Cells," <i>Gut</i> 52:1308-1316 (2003).								
							<u>-</u>		
		· · · · · · · · · · · · · · · · · · ·							
			•						
				<del></del>	<del></del>				
				,			-		
					<u>-</u>		•		
EXAMINER	B.L. S.	in	DATE CO	NSIDERED	71	19/04	*		
	itial citation conside ext communication (		ough citation if not in cor	nformance ar	nd not cons	sidered. Incl	ude copy of this		

Sheet 1 of 3 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUBSTITUTE FORM PTO-1449 Attorney Docket No. 50026/012004 (MODIFIED) Serial No. To Be Assigned Applicant Keiya Ozawa INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date July 13, 2001 (Use several sheets if necessary) Group (37 C.F.R. §1.98(b)) IDS Filed July 13, 2001 U.S. PATENTS Patent Number Issue Date Patentee Examiner's Subclass Filing Date Initials (If Appropriate) FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION Publication Country or Class Sunclass Dog ment Translation Examiner's Patent Office initiale Number Date (Yes/No) OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Aki et al., "Identification and Characterization of Positive Regulatory Elements in the Human Glyceraldehyde 3-Phosphate Dehydrogenase Gene Promoter," J. Biochem. 122:271-278 (1997). Avaios, "Molecular Analysis of the Granulocyte Colony-Stimulating Factor Receptor," Blood 88:761-777 (1996). Berthols et al., "Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture," Proc. Natl. Acad. Sci. USA 83:2496-2500 (1986). Blaese et al., "T Lymphocyte-Directed Gene Therapy for ADA-SCID: Initial Trial Results After 4 Years," Science 270:475-480 (1995). Bordignon et al., "Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA-Immunodeficient Patients," Science 270:470-475 (1995). Conneally et al., "Rapid and Efficient Selection of Human Hematopoletic Cells Expressing Murine Heat-Stable Antigen as an Indicator of Retroviral-Mediated Gene Trensfer," Blood 87:456-464 Daniellan et al., "Identification of Residues in the Estrogen Receptor That Confer Differential Sensitivity to Estrogen and Hydroxytamoxifen," Molecular Endocrinology 7:232-240 (1993). Dong et al., "Distinct Cytoplasmic Regions of the Human Granulocyte Colony-Stimulating Factor Receptor Involved in Induction of Proliferation and Maturation," Molecular and Cellular Biology 13:7774-7781 (1993). Dunbar et al., "Gene Transfer into Hematopoletic Progenitor and Stem Cells: Progress and Problems," Stem Cells 12:563-576 (1994). Fukunaga et al., "Growth and Differentiation Signals Mediated by Different Regions in the Cytoplasmic Domain of Granulocyte Colony-Stimulating Factor Receptor," Cell 74:1079-1087 BX. Lision FIATE PAREITOPE 7/19/04 EXAMINITE

Sheet 2 of 3 SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE Attorney Docket No. 50026/012004 (MODIFIED) PATENT AND TRADEMARK OFFICE Serial No. To Be Assigned Applicant Keiya Ozawa INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date July 13, 2001 (Use several sheets if necessary) Group 1634 (37 C.F.R. §1.98(b)) IDS Filed July 13, 2001 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Fukunaga et al., "Functional domains of the granulocyte colony-stimulating factor receptor," The EMBO Journal 10:2855-2865 (1991). Fukunaga et al., "Purification and Characterization of the Receptor for Murine Granulocyte Colonystimulating Factor," The Journal of Biological Chemistry 265:14008-14015 (1990). Gabbianelli et al., "Multi-Level Effects of fit3 Ligand on Human Hematoppiesis: Expression of Putative Stem Cells and Proliferation of Granulomonocytic Progenitors/Monocytic Precursors," Blood 88:1661-1670 (1995). Gossen et al., "Tight control of gene expression in mammalian cells by letracycline-responsive promoters," Proc. Natl. Acad. Sci. USA 89:5547-5551 (1992). Hanania et al., "Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model," Cancer Gene Therapy 1:21-25 (1994). Hanju et al., "Extracellular Domain of Granulocyte-Colony Stimulating Factor Receptor," Archives of Biochemistry and Biophysics 324:344-356 (1995). Hockenbery et al., "BcI-2 Functions in an Antioxidant Pathway to Prevent Apoptosis." Cell 75:241-251 (1993). Hollenberg et al., "Use of a conditional MyoD transcription factor in studies of MyoD transactivation and muscle determination," Proc. Natl. Acad. Sci. USA 90:8028-8032 (1993). Hope et al., "trans-Dominant Inhibition of Human Immunodeficiency Virus Type 1 Rev Occurs through Formation of Inactive Protein Complexes," Journal of Virology 66:1849-1855 (1992). Hudak et al., "FLT3/FLK2 Ligand Promotes the Growth of Murine Stern Cells and the Expansion of Colony-Forming Cells and Spicen Colony-Forming Units," Blood 85:2747-2755 (1995). lkebuchi et al., "Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoletic progenitors," Proc. Natl. Acad. Sci. USA 85:3445-3449 (1988). Ito et al., "Development of a Novel Selective Amplifier Gene for Controllable Expansion of Transduced Hematopoietic Cells," Blood 90:3884-3892 (1997). Karlsson, "Treatment of Genetic Defects in Hematopoietic Cell Function by Gene Transfer," Blood 78:2481-2492 (1991). Littlewood et al., "A modified cestrogen receptor ligend-binding domain as an improved switch for the regulation of heterologous proteins," Nucleic Acids Research 23:1686-1690 (1995). Luo et al., "Oligomerization activates c-Raf-1 through a Ras-dependent mechanism," Nature 383:181-185 (1996). 2/19/04

Sheet 3 of 3 SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE Attorney Docket No. 50026/012004 PATENT AND TRADEMARK OFFICE (MODIFIED) Serial No. To Be Assigned Applicant Keiya Ozawa INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date July 13, 2001 (Use several sheets if necessary) Group 1634 IDS Filed (37 C.F.R. §1.98(b)) uly 13, 2001 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Medin et al., "A Bicistomic Therapeutic Retroviral Vector Enables Sorting of Transduced CD34+ Cells and Corrects the Enzyme Deficiency in Cells From Gaucher Patients," Blood 87:1754-1762 (1996). Molineux et al., "The Effects on Hematopoiesis of Recombinant Stem Cell Factor (Ligand for c-kit) Administered in Vivo to Mice Either Alone or in Combination With Granulocyte Colony-Stimulating Factor," Blood 78:961-966 (1991). Nagamune et al., "The development of artificial receptor-expressing cells capable of being switched by antigen-antibody reactions," Pharmada 38(6):474-478 (2000). (English translation attached). Pawliuk et al., "Selection of Retrovirally Transduced Hematopoietic Cells Using CD24 as a Marker of Gene Transfer," Blood 84:2868-2877 (1994). Picard et al., "A Movable and Regulable Inactivation Function within the Steroid Binding Domain of the Glucocorticold Receptor," Cell 54:1073-1080 (1988). Planelles et al., "A new reporter system for detection of retroviral infection," Gene Therapy 2:369-376 (1995). Richardson et al., "Preselection of Transduced Murine Hematopoietic Stem Cell Populations Leads to Increased Long-Term Stability and Expression of the Human Multiple Drug Resistance Gene," Blood 86:2579-2589 (1995). Roemer et al., "Modulation of cell proliferation and gene expression by a p53-estrogen receptor hybrid protein," Proc. Natl. Acad. Sci. USA 90:9252-9258 (1993). Romano et al., "Recent Advances, Prospects and Problems in Designing New Strategies for Oligonucleotide and Gene Delivery in Therapy," in vivo 12:59-68 (1998). Somentino et al., "Selection of Drug-Resistant Bone Marrow Cells in Vivo After Retroviral Transfer of Human MDR1," Science 257:99-103 (1992). Takebayashi et al., "Hormone-induced Apoptosis by Fas-Nuclear Receptor Fusion Profeins: Novel Biological Tools for Controlling Apoptosis in Vivo, Cancer Research 58:4164-4170 (1996). Tong et al., "In Vivo Administration of Recombinant Methionyl Human Stem Cell Factor Expands the Number of Human Marrow Hernatopoletic Stem Cells," Blood 82:784-791 (1993). Walsh et al., "A Functionally Active Retrovirus Vector for Gene Therapy in Fanconi Anemia Group C," Blood 84:453-459 (1994). Welte et al., "Filgrastim (r-metHuG-CSF): The First 10 Years," Blood 88:1907-1929 (1996). White et al., "Molecular Analysis of the Region of Distal 1p Commonly Deleted in Neuroblastoma." European Journal of Cancer 33:1957-1961 (1997).

Yoshikawa et al., "Distinct signal transitio

Bollin

7/19/04

Sheet 1 of 1

01100212122	FORM PTO 4445		LIEUT OF OCCUPANT	Attorney D	ncket No				
SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT (MODIFIED) PATENT AND TRAD			MENT OF COMMERCE TRADEMARK OFFICE	Attorney Docket No.		50026/01	50026/012004		
				Serial No.		09/905,59	09/905,591		
	INFORMATI	וטאו טופטי טפוזים	Applicant		Keiya Oza	Keiya Ozawa et al.			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))					Filing Date		July 13, 2001		
					Group		1634		
					IDS Filed		April 16, 2004		
			U.S. PATENTS						
Examiner's	Examiner's Patent Number Issue Date Patentee				Class	Subclass	Filing Date		
Initials							(If Appropriate)		
	FORE	IGN PATENT OF	R PUBLISHED FOREIGN	PATENT AF	PPLICATIO	)N			
Examiner's	Document	Publication	Country of	7	Class	Subclass	Translation		
Initials	Number	Date	Patent Office	e			(Yes/No)		
BIK	WO 93/10151	May 27, 1993	WIPO						
	OTHER DOCL	IMENTS (INCLUI	DING AUTHOR, TITLE, D	ATE, PLACE	E OF PUBI	LICATION)			
BYL	Gearing et al., "The IL-6 Signal Transducer, gp130: An Oncostatin M Receptor and Affinity Converter for the LIF Receptor," Science 255(5050):1434-1437 (1992).								
			/				···		
EXAMINER	B.X - L	sia	DATE COI	NSIDERED	2/1	19/04			
	tial citation consider								